摘要
为评价表达牛病毒性腹泻-黏膜病病毒(BVDV)E2基因重组卡介苗(rBCG)的初步免疫效果,本研究分别将rBCG-pMV261-E2和rBCG-pMV361-E2免疫实验用大耳白兔,通过间接ELISA方法和T淋巴细胞转化试验分别检测兔体内体液免疫和细胞免疫应答水平。结果显示在体液免疫方面,两组rBCG均从第7 d开始产生BVDV抗体,抗体水平逐渐上升,在42 d达到峰值,并且rBCG-pMV361-E2刺激所产生的抗体水平始终高于rBCG-pMV261-E2;而rBCG血清中的抗结核菌抗体水平与正常BCG无显著差异,与BVDV阳性对照组和阴性对照组之间则差异显著;在细胞免疫方面,与阴性对照组相比,两组rBCG与BVDV灭活苗相同,免疫实验兔后淋巴细胞对特异性刺激均有明显的增殖。表明两组rBCG免疫实验兔后均使其产生了体液免疫应答和细胞免疫应答,为进一步研制BVDV新型基因工程疫苗奠定基础。
To evaluate the efficacy of recombinant Bacille Calmette-Gu6rin （rBCG） vaccines expressing the E2 gene of bovine viral diarrhea-mucosal disease virus （BVDV）, the rabbits were intramuscularly injected with two rBCG vaccines of rBCG-pMV261-E2 and rBCG-pMV361-E2, respectively, and the blood samples were collected at six weeks post vaccination （pv） to examine the humoral and cellular immunoresponses by indirect ELISA and lymphocyte transformation test. The results showed the antibodies against BVDV in the two rBCG groups were detectable at 7 days pv and reached the peak at 42 days. While, the antibody level in rBCG-pMV361-E2 immunized group was always higher than that in rBCG-pMV261-E2 immunized group, but there was no significant difference of antibody level between rBCG and BCG immunized group. In addition, the specific lymphocyte proliferations were observed in both rBCG and BVDV immunized group. The results indicated that the two rBCGvaccines were able to efficiently stimulate the humoral and cellular immunologic responses in immunized rabbits. This study laid foundation for study on new type engineering vaccine against BVDV.
出处
《中国预防兽医学报》
CAS
CSCD
北大核心
2014年第2期146-149,共4页
Chinese Journal of Preventive Veterinary Medicine
基金
国家科技支撑计划(2011BAI03B02-1)
国家自然科学基金(31072140)
吉林省科技厅科技成果转化促进计划(20125067)
吉林农业大学博士启动基金(201209)
